STOCK TITAN
  1. Home
  2. News
  3. PALI

Palisade Bio, Inc. - PALI STOCK NEWS

Welcome to our dedicated page for Palisade Bio news (Ticker: PALI), a resource for investors and traders seeking the latest updates and insights on Palisade Bio stock.

Palisade Bio, Inc. (Symbol: PALI) is a clinical-stage biopharmaceutical company dedicated to developing therapeutic solutions aimed at preserving the integrity of the intestinal barrier. The company's primary focus is on innovative treatments for inflammatory bowel diseases (IBD) such as ulcerative colitis (UC) and Crohn's disease (CD).

Palisade Bio’s strategic product portfolio includes PALI-2108, a promising drug candidate currently under development for treating IBD conditions. The company is also actively researching PALI-1908, a potential therapeutic that may expand its impact in gastrointestinal health.

Recently, Palisade Bio announced significant progress in its pipeline and secured strategic partnerships to further its research and development efforts. Notably, Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the latest offering, underscoring the financial community's confidence in the company's vision and potential.

Palisade Bio's commitment to advancing healthcare solutions is backed by a robust team and dedicated research initiatives. The company frequently updates its stakeholders with the latest developments and forward-looking statements. For more information or inquiries, Jenene Thomas from the JTC Team, LLC can be contacted at 833-475-8247 or via email at PALI@jtcir.com.

News

Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders

Rhea-AI Summary
Palisade Bio, Inc. (Nasdaq: PALI) has appointed two renowned gastroenterologists, Dr. Bruce Sands and Dr. Florian Rieder, to its Clinical Advisory Board (CAB) to advise on the development of novel therapeutics for serious chronic gastrointestinal diseases, with a focus on Inflammatory Bowel Disease (IBD). The company's lead asset PALI-2108 for the treatment of ulcerative colitis is on track for a Phase 1 clinical study launch next year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
News

Palisade Bio Announces Exercise of Previously Issued Warrants for $2.5 Million

Rhea-AI Summary
Palisade Bio, Inc. announced an agreement to exercise existing warrants, resulting in gross proceeds of approximately $2.5 million prior to deducting placement agent fees and estimated offering expenses. The company will issue new unregistered warrants to purchase shares of common stock in a private placement. The net proceeds from the offering will be used for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-35.42%
Tags
none
-
News

Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn’s & Colitis Congress

Rhea-AI Summary
Palisade Bio, Inc. presented positive preclinical data of its lead asset, PALI-2108, at the Crohn’s & Colitis Congress. The preclinical data showed that PALI-2108 is safe and well-tolerated, orally delivered, and colon-activated, with low systemic exposure. The company is advancing PALI-2108 for the treatment of moderate-to-severe ulcerative colitis (UC) towards a Phase 1 clinical study expected to commence in 2024. The preclinical studies demonstrated that PALI-2108 offers localized bioactivation, colon-specific distribution, similar target engagement to other PDE4 inhibitors, dose-dependent efficacy in a mouse UC model, and no systemic toxicity in dogs, with a large therapeutic window due to local activation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
84.62%
Tags
clinical trial
News

Palisade Bio Selected for Poster Presentation at the 2024 Crohn’s & Colitis Congress

Rhea-AI Summary
Palisade Bio, Inc. (Nasdaq: PALI) announced that its abstract has been accepted for poster presentation at the Crohn’s & Colitis Congress. The poster presentation, titled 'Local Bioactivation and Efficacy of PALI-2108: A Promising PDE4 Inhibitor Prodrug for Ulcerative Colitis Treatment', will take place on January 26, 2024, in Las Vegas, NV.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.89%
Tags
none
-
News

Palisade Bio Announces Receipt of Second Milestone Payment from the US Crohn’s and Colitis Foundation for Development of PALI-2108

Rhea-AI Summary
Palisade Bio, Inc. (Nasdaq: PALI) receives second milestone payment for co-development partner Giiant Pharma, Inc. from the US Crohn’s and Colitis Foundation for the treatment of moderate-to-severe ulcerative colitis (UC).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.33%
Tags
none
-
News

Palisade Bio Reports Third Quarter 2023 Financial Results and Provides Business Outlook

Rhea-AI Summary
Palisade Bio, Inc. (Nasdaq: PALI) reported its financial results and business outlook, including a transformative transaction for the development of novel therapeutics for inflammatory bowel disease (IBD). The lead program, PALI-2108, an oral prodrug therapy for moderate-to-severe ulcerative colitis, is set to begin Phase 1 clinical study in 2024. The company has a strong financial position to achieve significant milestones into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.92%
Tags
earnings
News

Palisade Bio to Participate at the Virtual Investor Ask the CEO Conference

Rhea-AI Summary
Palisade Bio CEO to participate in Virtual Investor Ask the CEO Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
conferences
-
News

Palisade Bio Announces Closing of $2 Million Registered Direct Offering Priced At Market Under Nasdaq Rules

Rhea-AI Summary
Palisade Bio, Inc. has closed its registered direct offering, raising $1,965,094.32 in gross proceeds. The company plans to use the net proceeds for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.48%
Tags
offering
-
News

Palisade Bio Appoints GI Clinical Expert and Biotech Entrepreneur Mitchell Jones, M.D., Ph.D. as Chief Medical Officer

Rhea-AI Summary
Palisade Bio appoints Mitchell Jones, M.D., Ph.D. as Chief Medical Officer. Dr. Jones has a proven track record in developing GI therapeutics. Palisade Bio aims to offer new treatment options for IBD patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.95%
Tags
management
News

Palisade Bio Announces $2 Million Registered Direct Offering of Common Stock Priced At Market Under Nasdaq Rules

Rhea-AI Summary
Palisade Bio, Inc. announces definitive agreements for the purchase of 2,339,398 shares of common stock for gross proceeds of $1,965,094.32 in a registered direct offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-45.83%
Tags
offering

FAQ

What is the current stock price of Palisade Bio (PALI)?

The current stock price of Palisade Bio (PALI) is $1.75 as of December 20, 2024.

What is the market cap of Palisade Bio (PALI)?

The market cap of Palisade Bio (PALI) is approximately 5.3M.

What is Palisade Bio, Inc.'s core business?

Palisade Bio is a clinical-stage biopharmaceutical company focused on developing therapeutics to protect the integrity of the intestinal barrier.

What diseases is Palisade Bio targeting with its therapeutics?

The company focuses on treating inflammatory bowel diseases (IBD) such as ulcerative colitis (UC) and Crohn's disease (CD).

What are the key products in Palisade Bio's portfolio?

Key products include PALI-2108 for IBD treatment and PALI-1908, which is currently in the research phase.

Who is the exclusive placement agent for Palisade Bio's latest offering?

Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the offering.

How can I contact Palisade Bio for more information?

You can contact Jenene Thomas from the JTC Team, LLC at 833-475-8247 or via email at PALI@jtcir.com.

What stage is Palisade Bio in its development?

Palisade Bio is currently in the clinical stage of developing its therapeutic products.

Does Palisade Bio have any ongoing research projects?

Yes, Palisade Bio is actively researching PALI-1908 in addition to developing PALI-2108 for IBD treatment.

What recent achievements has Palisade Bio announced?

The company has announced significant progress in its drug pipeline and secured strategic partnerships to further research and development.

What is the significance of PALI-2108?

PALI-2108 is a promising drug candidate specifically being developed to treat inflammatory bowel diseases like UC and CD.

Who are the target stakeholders for Palisade Bio's updates?

The target stakeholders include investors, medical professionals, and partners interested in the company's advancements and therapeutic developments.

Stock PALI logo
Palisade Bio, Inc.

Nasdaq:PALI

PALI Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

PALI Stock Data

5.35M
1.31M
1.88%
3.58%
2.82%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
CARLSBAD